Categories Analysis, Cannabis

CannTrust may be cheap, but stay away from this pot stock

Shares of CannTrust Holdings (NYSE: CTST) have plunged over 80% in the past 12 months, making it quite cheap with respect to its cannabis growing potential. It might look like an irresistible offer at this price, for a marijuana stock that comes with immense growth potential. Yet, it’s safe to stay clear.

If you have not been following the stock, the logic wouldn’t strike you too quickly. The Ontario-based company has been embroiled in two major scandals recently, making it quite difficult to convince investors that it is a credible firm.

Canopy Growth Co-CEO Bruce Linton exits
Image by Rex Medlen from Pixabay

The first was in July when it was discovered that CannTrust illegally grew marijuana in rooms hidden behind walls, besides exporting some of this to countries such as Denmark. Worse, the management allegedly knew about these wrongdoings but remained silent about it.

CannTrust had fired its CEO Peter Aceto following the incident.

Regulators are yet to announce a punishment, which could be anywhere between cutting down its inventory to scrapping its license. Though a takeover could put a gradual end to CannTrust’s woes, uncertainty surrounding the penalty faced by the company makes it an unattractive takeover target.  

READ: Aurora, Canopy Growth to be the biggest gainers in Cannabis 2.0

Even if a potential buyer comes forward, it will be tasked with the cumbersome job of convincing the regulators that its practices would change following the merger.

Amidst all this, CannTrust once again came under the hammer after the Ontario Cannabis Store returned about $3 million worth of its products for not conforming to the supplier agreement.  This double whammy almost wipes of CannTrust’s credibility and makes regaining investor confidence a major hurdle.

Also Read:  Yelp (YELP): Revenue recovery depends significantly on COVID-19 environment

On a whole, pot stocks may not be performing as one might have expected. Yet, when so many credible firms are out in the market, it makes little sense to try CannTrust even at the given valuation.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Novavax (NVAX) tops Q2 2020 bottom line targets, misses revenue views

Novavax (NASDAQ: NVAX) reported a loss of $17.5 million or $0.30 per share for the second quarter of 2020. Revenue jumped to $35.54 million in Q2 from $3.36 million in

Tilray Q2 loss widens despite revenue growth; results miss Cannabis company Tilray, Inc. (NASDAQ: TLRY) Monday reported a wider net loss for the second quarter of 2020, despite a marked increase in revenues. Revenues of the Canada-based company

Infographic: Duke Energy Q2 2020 Earnings Results

Duke Energy (NYSE: DUK) reported second-quarter financial results before the market opened on Monday.  The energy holding company surpassed earnings expectations by 5 cents per share during the quarter. DUK

2 thoughts on “CannTrust may be cheap, but stay away from this pot stock

Comments are closed.